Christina M Zettler

Mrs. Christina M Zettler

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
HSHelmneh M. Sineshaw
Helmneh M. Sineshaw
CZChristina M Zettler
Christina M Zettler
JPJennifer Prescott
Jennifer Prescott
MGMahek Garg
Mahek Garg
SCSamhita Chakraborty
Samhita Chakraborty
CWChing‐Kun Wang
Ching‐Kun Wang
Background: Although initial treatment of diffuse large B‐cell lymphoma (DLBCL) with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R‐CHOP) can be effective, up to 50% of patients will develop refractory or relapsed (R/R) disease. This study aimed to provide contemporary data on characteristics, treatment patterns, and outcomes for R/R‐DLBCL.Methods: Patients with incident (January 2016 to March 2021) DLBCL age ≥18 years who initiated first‐line (1L) therapy were identified from the COTA real‐world database. Baseline characteristics, treatment patterns, and real‐world outcomes, including time to next treatment (rwTTNT) and overall survival (rwOS), were assessed for the study population and by line of therapy (LOT).Results: A total of 1347 eligible DLBCL patients were identified. Of these, 340 (25.2%) proceeded to receive 2L, of whom 141 (41.5%) proceeded to receive 3L, of whom 51 (36.2%) proceeded to receive 4L+. Most common treatments were R‐CHOP in 1L (63.6%), stem cell transplant (SCT) in 2L (17.9%), polatuzumab vedotin, bendamustine, and rituximab (Pola‐BR) in 3L (9.9%), and chimeric antigen receptor T‐cell therapy (CAR‐T) in 4L (11.8%). Treatment patterns were more variable in later LOTs. One‐ and 3‐year rwOS from 1L initiation were 88.5% and 78.4%, respectively. Patients who received later LOTs experienced numerically lower 1‐ and 3‐year rwOS (from 2L initiation: 62.4% and 46.4%, respectively).Conclusions: In this real‐world analysis, 25.2% of patients experienced R/R‐DLBCL after 1L with poor outcomes. Given the findings of this study, there is a high unmet need for novel, safe, and effective treatment options for patients with R/R DLBCL.

14 October 2024 in Blood Neoplasia
Verified
Journal Article
Open access
MDMatthew S. Davids
Matthew S. Davids
JAJacob Ambrose
Jacob Ambrose
ENEnrico de Nigris
Enrico de Nigris
JPJennifer Prescott
Jennifer Prescott
SLSiyang Leng
Siyang Leng
MSMazyar Shadman
Mazyar Shadman
• Targeted agents have revolutionized CLL treatment, shown by decreased use of chemoimmunotherapy and increased use of targeted inhibitors from 2014 to 2023. • Median times to events were generally shorter for each subsequent LOT; unmet need persists among patients with CLL receiving ≥2L LOT.

1 April 2025 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
SDSharlene Dong
Sharlene Dong
AKAnkit Kansagra
Ankit Kansagra
GKGurbakhash Kaur
Gurbakhash Kaur
ABAnna Barcellos
Anna Barcellos
ABAndrew J. Belli
Andrew J. Belli
CWChing-Kun Wang
Ching-Kun Wang
PURPOSE: Accurate survival data are critical for high-quality outcomes research. It has been documented that mortality data capture in the real-world setting may be prone to missingness. Our study sought to evaluate the validity of a composite real-world mortality variable compared with the National Death Index (NDI) as the gold standard. METHODS: This was a retrospective, observational research study of patients with hematologic malignancies treated in the United States. Adult patients diagnosed with one of the following cancers between January 1, 2012, and December 31, 2020, were included: AML, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, multiple myeloma, and myelodysplastic syndrome. Validation metrics (sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]) and date concordance (exact, ±7, 15, and 30 days) were assessed. RESULTS: The final study population included N = 21,565 patients across seven cancer types. Validation metrics showed high sensitivity (87.8%), specificity (95.7%), PPV (90.9%), and NPV (94.1%) when comparing the composite real-world mortality variable with the NDI. Exact date concordance was observed in 88.0% of patients, and concordance rates for 7-, 15-, and 30-day intervals were 93.1%, 93.8%, and 94.3%, respectively. CONCLUSION: Our study found that a composite mortality variable leveraging multiple data sources yields high validity when compared against the gold-standard NDI. Given evidence highlighting the challenges of mortality data documentation in the real-world setting, the use of a composite mortality variable can provide significant benefits in quality of documentation and research results.

1 January 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
CLCurtis Lachowiez
Curtis Lachowiez
ABAnna Barcellos
Anna Barcellos
CZChristina M Zettler
Christina M Zettler
ABAndrew J. Belli
Andrew J. Belli
LFLaura L. Fernandes
Laura L. Fernandes
RSRonan Swords
Ronan Swords
PURPOSE: For patients with newly diagnosed AML not suitable for intensive induction chemotherapy, venetoclax (VEN) plus azacitidine (AZA) is a standard of care therapy. This study describes real-world (rw) treatment patterns and outcomes of patients with AML receiving initial VEN-based therapy. METHODS: Patients age ≥18 years diagnosed with AML who received first-line (1L) VEN-based therapy and had available dosing information were included from the COTA rw, electronic health records–based database. Patients with missing/imprecise key study dates were excluded. The index date for the study was the date of 1L initiation, unless otherwise noted. Rw time to next treatment, rw event-free survival, and rw overall survival (rwOS) were analyzed using the Kaplan-Meier method. RESULTS: A total of 331 patients met the inclusion criteria, of which the majority were male, White, and treated in community practices. In patients with available molecular data for the given marker, 8.8%, 19.7%, 11.0%, and 19.7% had mutations in IDH1 , IDH2 , FLT3 -ITD, and NPM1 , respectively. Following 1L, 115 patients initiated second-line (2L) therapy, of which 26.1% received intensive chemotherapy, 60.9% received low-intensity regimens, and 8.7% received investigational therapy. The median rwOS overall was 13.9 months and differed by mutation status (13.1 months for IDH1 -positive patients, 42.0 months for IDH2 -positive patients, not reached for FLT3 -ITD–positive patients, and 42.0 months for NPM1 -positive patients). CONCLUSION: The median rwOS for this study was comparable with results in the VIALE-A trial, despite the community-based nature of these data. There was no clear standard of care for patients who received 2L+ therapy. These data highlight the need for novel treatment for patients with AML following 1L VEN-based therapy.

30 April 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
EPElizabeth Dianne Pulte
Elizabeth Dianne Pulte
LFLaura L. Fernandes
Laura L. Fernandes
KNKelly Norsworthy
Kelly Norsworthy
JWJoseph Wynne
Joseph Wynne
EHEric Hansen
Eric Hansen
ACAngelo de Claro
Angelo de Claro
PURPOSE: The US Food and Drug Administration has approved multiple new treatments for AML since 2017 based on demonstrated efficacy and safety in clinical trials. However, the uptake of new treatments and effectiveness in the routine clinical practice are largely unknown. METHODS: A retrospective observational study was conducted to examine first-line therapy in patients with AML who were treated at institutions providing data to the COTA database. Information on demographics, disease characteristics, treatments, and outcomes was collected and analyzed descriptively. RESULTS: Among the 2,516 patients eligible for inclusion in our analysis, cytarabine-based intensive chemotherapy (IC w/cytara) was the most commonly used treatment, followed by hypomethylating agents (HMA) with venetoclax (HMA+ven), HMA alone, and investigational treatment. Use of HMA+ven increased over time since its approval in 2018, whereas use of IC w/cytara and HMA alone decreased. Complete remission rates were 45% overall and highest in patients treated with IC w/cytara (61%) or investigational therapy (62%). CONCLUSION: Overall survival was highest for patients treated with IC w/cytara, although differences in baseline patient characteristics make direct comparison infeasible. Uptake of HMA+ven as a first-line treatment for patients with AML has been more rapid compared with other newly approved therapies. Outcomes for patients treated in routine practice were similar to those seen in clinical trials. Further research may be helpful in characterizing real-world effectiveness and safety in specific subpopulations and disease subtypes.

3 October 2025 in Future Oncology
Verified
Journal Article
Closed access
HSHelmneh M. Sineshaw
Helmneh M. Sineshaw
CBClaire Bai
Claire Bai
ENEnrico de Nigris
Enrico de Nigris
JPJennifer Prescott
Jennifer Prescott
UOUzor Ogbu
Uzor Ogbu
CWChing-Kun Wang
Ching-Kun Wang
Approvals of Bruton's tyrosine kinase inhibitors (BTKis) and other novel agents have changed the Mantle Cell Lymphoma (MCL) treatment paradigm, necessitating assessment of contemporaneous, real-world (rw) treatment and outcomes by line of therapy (LOT). Patients diagnosed with MCL on or after 1 January 2012 who initiated first-line (1 L) treatment in the COTA database were eligible, excluding those with concurrent primaries, history of hematologic malignancies, clinical trial participation, or missing/imprecise key dates. Rw time to next treatment (rwTTNT) and overall survival (rwOS) were evaluated using the Kaplan-Meier method from LOT start (index). Of 499 patients, most were ≥ 50 years (94.8%), male (71.5%), treated in the community (58.7%), and diagnosed with stage III/IV disease (91.2%). The most common 1 L regimen was bendamustine+rituximab (BR)±R maintenance (12.6%/23.0%, respectively). Fifty (10.0%) patients received 1 L autologous stem cell transplant. One hundred and seventy-three patients (34.7%) received 2 L, of which 72 (41.6% of 2 L) received 3 L, of which 29 (40.3% of 3 L) received 4 L +. BTKi monotherapy was the most frequently administered therapy in 2 L (26.0%).Median rwTTNT and rwOS from 1 L to 4 L were 36.8-3.2 and 86.2-8.7 months, respectively. Outcomes of patients who received 2 L+ for MCL remain poor, highlighting unmet need in the contemporary treatment paradigm.